Cognos Therapeutics believes its SINNAIS implantable pump can increase efficacy of CAR T therapies for the treatment of leukemia.
- Dr. Susan Alpert, MD, PhD, Joins Cognos Therapeutics as Lead Regulatory Consultant
- Cognos’ SINNAIS Smart Implantable Pump to Improve CAR T Cell Efficacy in Solid tumors
- Cognos Therapeutics plans to conduct a twenty-patient human clinical trial using direct delivery of Herceptin (a Genentech drug) to prove drug safety in the brain region.
- Dr. Francis Ali-Osman
- FDA’s Role In The Precision Medicine Initiative Pushes Combination Drug Devices to New Heights Sharing Cognos Therapeutics Vision.